Got a Question?
1-877-666-5222


New Customer? Register Here.

View Shopping Cart
0 item(s) - $0.00

Company Announcements

  Announcement

FOR IMMEDIATE RELEASE

Contact:         David Ball, Ball Consulting Group, LLC

                       Office: 617-243-9950

                       Mobile: 617-548-7809

                       Email: david@ballcg.com

 

CANTRELL DRUG COMPANY ENHANCES COMPOUNDING SAFETY WITH CLOSED VIAL FILLING SYSTEM FROM ASEPTIC TECHNOLOGIES

 

Little Rock, Ark. (September 10, 2014)Cantrell Drug Company today announced it has entered into an exclusive agreement to become the first human drug compounding outsourcing facility to utilize Aseptic Technologies’ closed vial system for aseptic filling of injectable drugs. Outsourcing facilities were created under the federal Drug Quality and Security Act (DQSA) enacted in November 2013.

Under the agreement, Cantrell Drug Company will prepare sterile compounded medications with Aseptic Technologies’ Crystal® Closed Vial Technology, which was designed to increase patient safety by vastly reducing the risk of contamination during the complex filling process used by sterile compounding pharmacies and outsourcing facilities. The new technology simplifies and reduces the risk associated with the glass vial filling process used by pharmaceutical manufacturers. Additionally, it provides easier handling for pharmacists and hospital staff who dispense medication.

“This technology represents a revolutionary advance for Cantrell Drug Company, as well as for the sterile product industry in general,” said Dell McCarley, Chief Executive Officer of Cantrell Drug Company. “We decided to invest in the Crystal Closed Vial Technology because of the high level of quality assurance it will offer to our customers in the hospital market and, by extension, the patients they serve.”

Under the closed vial process, each vial will be assembled in a clean room and sterilized by gamma irradiation before being delivered, ready to fill, to Cantrell Drug Company. A Crystal robotic system in a SKAN isolator fills each vial by piercing the elastic stopper with a special needle, delivering the liquid, and quickly re-sealing the opening with the zap of a laser. Vials are covered with a specially designed cap which health care providers eventually open to withdraw the sterile medication and administer to patients.

Cantrell Drug Company regularly supplies hospitals with sterile compounded medications, some of which are commercially unavailable and others that are simple admixtures. The company is the first U.S. compounding pharmacy to partner with Aseptic Technologies, a Belgium-based business which was spun out of GSK Biologicals, a subsidiary of global pharmaceutical company GlaxoSmithKline, in 2002.

“The collaboration with Cantrell Drug Company is a real opportunity to offer the benefits of the best aseptic technology to a broad base of patients in the United States,” said Aseptic Technologies CEO Patrick Balériaux. “At Aseptic Technologies, we are very proud and excited to actively participate with Cantrell Drug Company in continuing the improvement of drug safety in hospitals thanks to our Crystal Closed Vial Technology and our versatile robotic equipment to be installed in SKAN isolators.”

The Aseptic Technologies partnership continues Cantrell Drug Company’s tradition of innovation and investment to achieve the highest quality standards. Earlier this year, the company was among the first large-scale sterile compounding pharmacies in the nation to register as an outsourcing facility with the U.S. Food and Drug Administration (FDA) and follow more rigorous standards established by the DQSA. Prior to this registration, Cantrell Drug Company had voluntarily listed drug products with the FDA.

At Cantrell, patient safety is our top priority and that’s why we are always evaluating our operations and seeking opportunities to enhance quality assurance,” said Mike Pierce, President of Cantrell Drug Company. “We believe our investment in the closed vial technology takes us to another level of quality and safety, one that is unsurpassed in the sterile compounding industry.”

About Cantrell Drug Company

Founded in 1952, Cantrell Drug Company is a leading FDA-registered supplier of outsourced pharmacy preparations, specializing in providing custom IV admixtures, epidural preparations, PCA syringes, OR syringes, and drug shortage formulations with the highest quality standards.  Cantrell Drug Company provides sterile and non-sterile compounded preparations that meet the needs of patients, physicians, clinics and health care institutions. Based in Little Rock, Ark., Cantrell Drug Company retains state licenses nationwide, a DEA manufacturing license, and an FDA registration.

 

  Announcement

FOR IMMEDIATE RELEASE

Contact:         David Ball, Ball Consulting Group, LLC

                       Office: 617-243-9950

                       Mobile: 617-548-7809

                       Email: david@ballcg.com

 

CANTRELL DRUG COMPANY UPDATES FDA-REGISTRATION TO 503B OUTSOURCING FACILITY

 

Little Rock, Ark. (January 24, 2014)Cantrell Drug Company today announced amendment of its U.S. Food and Drug Administration (FDA) registration to include the new 503B “compounding outsourcing facility” designation established under the recently passed Drug Quality and Security Act so that it can continue to serve patients nationwide with high quality sterile medications that meet the most exacting quality standards.

“This was a natural move for us because we have been an FDA-registered provider of sterile admixture and drug shortage solutions for four years,” said Dell McCarley, Chief Executive Officer of Cantrell Drug Company.  “We have extensive experience with cGMP-focused policies and procedures, and our specially engineered facilities, state-of-the-art equipment, and rigorous training and testing ensure that our customers receive the highest quality products and services.”

Cantrell Drug Company is among the first pharmacies in the nation to register with the FDA following the passage of the new law, which aims to improve quality and safety among large-scale compounders who choose to adhere to more rigorous standards created under the federal Food, Drug and Cosmetic Act.

Prior to this registration, Cantrell Drug Company already voluntarily listed drug products with the FDA, which the company has regularly supplied to health care providers whose care for patients is threatened by shortages of certain medications.

Last year, McCarley joined five other industry executives to establish the Specialty Sterile Pharmaceutical Society, an organization dedicated to establishing stringent standards for specialty pharmaceutical manufacturing and to provide support for public policy that encourages the availability of outsourced sterile preparations.  He now serves as president of that organization.

McCarley also participated in the U.S. Pharmacopeial Convention’s Compounding Conclave, which met in December to discuss changes in the compounding profession and potential adjustments to USP standards in conjunction with new federal regulations.

“Our new FDA outsourcing facility designation will ensure that Cantrell can continue to serve the vital needs of hospitals and their patients,” said McCarley.  “We are here for them and we welcome their business.”

 

About Cantrell Drug Company

Founded in 1952, Cantrell Drug Company is a leading FDA-registered supplier of outsourced pharmacy preparations, specializing in providing custom IV admixtures, epidural preparations, PCA syringes, OR syringes, and drug shortage formulations with the highest quality standards.  Cantrell Drug Company provides sterile and non-sterile compounded preparations that meet the needs of patients, physicians, clinics and health care institutions. Based in Little Rock, Ark., Cantrell Drug Company retains state licenses nationwide, a DEA manufacturing license, and an FDA registration.

 

It Is Here! New Website Announcement

We are proud to announce the release of our newly redesigned website for Cantrell Drug Company. By updating our main site www.cantrelldrug.com we've been able to improve site navigation, connect with our clients and potential clients and provide enhanced information and decision tools for site visitors.

We are also excited to announce that Beta testing is currently underway for our Online Portal. This portal will allow our registered clients to request quotations, place orders, check status of current orders, review invoices, access to quality control report and FedEx Tracking information.